Business
NEONC Technologies Holdings, Inc. Appoints Dr. Alan Chiang to its Board of Directors
Dr. Chaing Expands NeOnc’s Expertise in Neurosurgery and Biotechnology WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies
About this update from Neonc Technologies Holdings, Inc.
[{"type":"text","content":"Dr. Chaing Expands NeOnc’s Expertise in Neurosurgery and Biotechnology\nWESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (to be listed on the NASDAQ Global Market under the symbol: NTHI), a clinical-stage medical biotechnology company, today announced that it has appointed Dr. Alan Chiang to its Board of Directors. Dr. Chiang, an esteemed neurosurgeon and entrepreneur, brings substantial expertise in minimally invasive spine surgery, brain tumor treatment, and biotechnology innovation. “We are excited to welcome Dr. Chiang to our Board,” said Dr. Thomas Chen, CEO of NeOnc. “His distinguished expertise in neurosurgery, coupled with his extensive experience in clinical research and entrepreneurial achievement, will be invaluable as we advance the delivery of our patented drug, NEO100. His visionary approach and commitment to progress resonate deeply with our mission.” Dr. Chiang is a practicing neurosurgeon at Fu Jen Catholic University Hospital in New Taipei City, Taiwan, where he also serves as an Associate Professor of Neurosurgery. Previously, he held pivotal roles at Mackay Memorial Hospital in Taipei, including Chief of the Division of Neurosurgery, and Deputy Chairman of the Department of Surgery. With a distinguished career in clinical practice and leadership, Dr. Chiang has earned recognition as a key contributor to both Taiwanese and international medical advancements. Beyond his clinical expertise, Dr. Chiang holds a Ph.D. from the Free University of Berlin, and is a dedicated researcher with a focus on brain cancer. His work includes molecular studies on WWOX and Sonic Hedgehog (SHH) pathways in glioma and glioblastoma, areas critical to understanding and treating these aggressive cancers. As a visionary entrepreneur, he founded Neucen Biomedical Inc. and Orion Biotech Inc., underscoring his commitment to driving innovation in biotechnology and advancing medical science. “It is a real privilege to join NeOnc, and I am eager to leverage my expertise in neurosurgery and biotechnology to support the Company’s mission of advancing groundbreaking healthcare solutions,” said Dr. Chiang. “This role presents an extraordinary opportunity to collaborate with visionary leaders dedicated to transforming patient outcomes.” “Dr. Chiang’s dedication to advancing neurosurgical techniques, ...